Brief: FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Cullinan Therapeutics

04/01/2022 12:01

Jan 4 (Reuters) - Cullinan Oncology Inc  CGEM.O :
    * FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR CULLINAN
ONCOLOGY’S CLN-081 IN PATIENTS WITH LOCALLY ADVANCED OR
METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Source text for Eikon:  ID:nGNXbXxD5D 
Further company coverage:  CGEM.O 

 ((Reuters.Briefs@thomsonreuters.com;;))